News

Novartis shipping 30 million doses of influenza vaccine well ahead of 2014-2015 season

BY Michael Johnsen

CAMBRIDGE, Mass. — Novartis on Wednesday announced that it has begun shipment of its seasonal influenza vaccines to customers in the U.S. market for the 2014-2015 season. Novartis plans to ship a minimum of 30 million doses of vaccines (Flucelvax and Fluvirin). 
 
Flucelvax, which is approved for use in adults 18 years of age and older, is manufactured with cell-culture technology, a modern, alternative production method for influenza vaccines to the traditional egg-based production method. 
 
Fluvirin is indicated for persons 4 years and older.
 
Novartis is the only influenza vaccine manufacturer to use production technologies based on cell-culture (Flucelvax) as well as eggs (Fluvirin), the company stated.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Impax Labs acquires two generic products from Actavis

BY Michael Johnsen

HAYWARD, Calif. — Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.
 
The acquisition includes one product marketed under an abbreviated new drug application — Ursodiol tablet — and one approved aNDA that is not yet marketed — Lamotrigine orally disintegrating tablet.
 
"The acquisition of these products from Actavis is just one example of our ongoing strategy of expanding our product offerings and portfolio with strategic business development projects," said Fred Wilkinson, president and CEO Impax Laboratories. "Successful implementation of our M&A and business development activities should complement our internal development programs and provide further long-term growth for the company."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

American Heart Association recognizes Kinney Drugs as top regional fundraiser

BY Antoinette Alexander

GOUVERNEUR, N.Y. — Kinney Drugs, which operates 100 drug stores in Central and Northern New York and Vermont, was recently recognized by the American Heart Association as the top fundraiser in its region as it presented the organization with a $17,420 check in support of the “Go Red for Women” movement.

The money raised is the result of an effort coordinated by Kinney Drugs during its month-long heart health initiative hosted at each of its 100 locations.

The company raised more than $10,000 by asking customers to make a donation in exchange for a red dress pin, the symbol of the “Go Red for Women” movement. Kinney Drugs also collected funds through several additional efforts, including vendor contributions, a chocolate bar sale and an employee fundraiser.

“This initiative was created not only to raise awareness about heart disease, but to take action against this silent killer,” said Jim Spencer, president of Kinney Drugs stores. “Our success is owed to the thousands of customers and employees who came together to support heart health in our communities.”

"We are steadfast supporters of the American Heart Association and Go Red for Women,” stated Bridget-Ann Hart, president and CEO of KPH Healthcare Services and member of the 2014 American Heart Association Go Red for Women leadership team. “As a pharmacy healthcare company, we are proud to promote heart health among our patients.”

The company’s initiative was developed with the American Heart Association to build awareness about the dangers of heart disease, provide resources for employees and customers to improve their heart health and help raise money for the “Go Red for Women” movement. The money raised will be used by the American Heart Association to support communities throughout New York and Vermont that are served by Kinney Drugs.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?